Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Anti-Aging
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Risks of TNF-α Blockers
Montreal - Drugs that block tumor necrosis factor alpha are showing great promise for the treatment of moderate to severe psoriasis, a condition that causes sufferers a good deal of misery and that can be frustratingly resistant to many treatments. However, the high potency comes with a tradeoff. Research indicates that blocking TNF-a may place patients at a higher risk for serious infections, notably tuberculosis.
Related Videos
Related Content
